Free Newsletter
Pediatricians say kids should take statins
Good news for makers of cholesterol meds: The market has just expanded. For the first time, the American Academy of Pediatrics is recommending that kids as young as 8 years old be given cholesterol drugs in hopes of preventing future heart disease. The influential doctors' group also wants doctors to routinely test young children's cholesterol levels, which isn't commonly done now. That testing would identify kids in need of drug therapy.
The AAP says its advice is based on new evidence showing that greater heart-disease risks begin developing early in life. Previously, the group had advised consideration of the drugs if kids older than 10 had tried and failed to lose weight.
Four statins are FDA-approved for pediatric use (with some age and developmental caveats): Mevacor, or lovastatin; Zocor, or simvastatin; Pravachol, or pravastatin; and Lipitor, or atorvastatin. Of those, only Pfizer's Lipitor remains on patent. But doctors could of course choose other branded meds for kids off-label.
- read the APP's release
- see the story in the Washington Post
- check out the post at the New York Times' blog
Related Articles:
U.K. aims to put 1.5M on preventive statins
Study: Statins cut cancer by 25%
Study: Diabetics should take statins
Comments
I used to think the Pediatric societies were one of the few physician organizations not bought out by big pharma.
I guess I was wrong!
Yeah right - instead of educating kids toward healthier eating and getting exercise, just let them keep eating junk and playing video games, because now there's a DRUG to take the edge off the risks there -- Brilliant. Talk about perpetuating a downward spiral -- the suggestion of mitigating "health risk" in this fashion is ludicrous.
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Comments (2) | Post a comment